Big Pharma just rewrote the rulebook in the obesity-treatment race. Pfizer has won the bidding for Metsera after a showdown with Novo Nordisk.
Dan Koh and Emaad Akhtar unpack how this US$10 billion move signals a pivot into GLP-1 drugs, why Novo walked away and what it all means for investors tracking the next trillion-dollar health-tech frontier.

Bigger Pic: From Building Maintenance to Space Tech
07:32

Mind Your Business: How Abel Richard went from managing power plants to selling 6 figure handbags
13:26

Morning Shot: Singaporeans Caught in the Middle East Conflict - The Race to Get Home
09:04